EP
MRKR icon

Eudaimonia Partners’s Marker Therapeutics MRKR Stock Holding History

Eudaimonia Partners’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150
Closed -$3K – 985
2021
Q1 		$3K Buy
+150
New +$3.43K ﹤0.01% 1405

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eudaimonia Partners's MRKR Position: Q2 2021 in Review

Eudaimonia Partners sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 150 shares — an estimated $3K sold.

Eudaimonia Partners first reported a position in MRKR in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

  • Eudaimonia Partners reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 150 Marker Therapeutics shares in Q2 2021, an estimated $3K.
  • Eudaimonia Partners first reported a position in Marker Therapeutics in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Marker Therapeutics position peaked at $3K in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.